MedTrace Logo

A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure

NCT00259116 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-04-15

No results posted yet for this study

Summary

This trial is a single center, open-label, dose-finding study of recombinant human relaxin (rhRlx) given intravenously (IV) to patients with stable, compensated CHF.

Conditions

  • Heart Failure, Congestive

Interventions

DRUG

Relaxin

Sponsors & Collaborators

  • Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

    lead INDUSTRY

Principal Investigators

  • Sam Teichman, MD · BAS Medical - Sponsor

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259116 on ClinicalTrials.gov